US 12,325,741 B2
Anti-Aβ antibodies and antigen-binding fragments thereof
Hua Ying, Shanghai (CN); Ling Zhang, Shanghai (CN); Jinping Shi, Shanghai (CN); Xiaomin Zhang, Shanghai (CN); Jiakang Sun, Shanghai (CN); Qiyue Hu, Shanghai (CN); and Weikang Tao, Shanghai (CN)
Assigned to Jiangsu Hengrui Medicine Co., Ltd., Lianyungang (CN); and Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai (CN)
Appl. No. 17/259,425
Filed by Jiangsu Hengrui Medicine Co., Ltd., Lianyungang (CN); and Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai (CN)
PCT Filed Jul. 16, 2019, PCT No. PCT/CN2019/096159
§ 371(c)(1), (2) Date Aug. 2, 2021,
PCT Pub. No. WO2020/015637, PCT Pub. Date Jan. 23, 2020.
Claims priority of application No. 201810782196.2 (CN), filed on Jul. 17, 2018.
Prior Publication US 2021/0371506 A1, Dec. 2, 2021
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 49/00 (2006.01); A61K 49/16 (2006.01); A61P 25/28 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01)
CPC C07K 16/18 (2013.01) [A61P 25/28 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/92 (2013.01)] 10 Claims
 
1. An anti-Abeta antibody or antigen-binding fragment thereof, wherein the anti-Abeta antibody specifically binds to human Abeta and comprises a heavy chain variable region comprising antibody heavy chain HCDR1, HCDR2 and HCDR3 regions and a light chain variable region comprising antibody light chain LCDR1, LCDR2 and LCDR3 regions, wherein the HCDR1 in comprises the amino acid sequence of SEQ ID NO: 17, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 18 or 52, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 27, and the LCDR1 comprises the amino acid sequence of SEQ ID NO: 20, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 21, and the LCDR3 comprises the amino acid sequence of SEQ IDNO: 22.